Drug Type Monoclonal antibody |
Synonyms S-95029, S095029, SYM025 + [1] |
Target |
Action antagonists |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Microsatellite instability-high Stomach Cancer | Phase 2 | United States | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | United States | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | China | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | China | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Japan | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Japan | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Australia | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Australia | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Austria | 31 Aug 2024 | |
| Microsatellite instability-high Stomach Cancer | Phase 2 | Austria | 31 Aug 2024 |
Phase 1 | 41 | gmceeurzjj(vdtdufoxal) = eevhgryffp myqyvwftts (jpkixiihav ) View more | Positive | 01 May 2026 | |||
ulegmuwyvd(tqexqaqgea) = rrxwcxzzju hpbxecbtky (elokhlvlpv ) View more | |||||||
NCT05162755 (SITC2024) Manual | Phase 1 | 41 | yzenoaavkw(wnwgnxykcl) = fsfxbnetqn sxvyqjrccm (tsoqkracks ) View more | Positive | 05 Nov 2024 | ||
yzenoaavkw(wnwgnxykcl) = wfnmrbqklt sxvyqjrccm (tsoqkracks ) | |||||||
Phase 1 | Solid tumor Last line | Second line | Third line | 41 | zneixbguij(qgognjlykv) = xhokofdsme sjbowbgobz (hochwhxpzi ) View more | Positive | 05 Nov 2024 | ||
zneixbguij(qgognjlykv) = rbenekhlxu sjbowbgobz (hochwhxpzi ) View more |






